CL2020002876A1 - Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420) - Google Patents

Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)

Info

Publication number
CL2020002876A1
CL2020002876A1 CL2020002876A CL2020002876A CL2020002876A1 CL 2020002876 A1 CL2020002876 A1 CL 2020002876A1 CL 2020002876 A CL2020002876 A CL 2020002876A CL 2020002876 A CL2020002876 A CL 2020002876A CL 2020002876 A1 CL2020002876 A1 CL 2020002876A1
Authority
CL
Chile
Prior art keywords
divisional application
infectious bronchitis
bronchitis vaccine
vaccine
component
Prior art date
Application number
CL2020002876A
Other languages
English (en)
Inventor
Freitas Carla Maria Batista De
Santos Maria Carolina Ferreira Dos
Paul Joseph Dominowski
Harmen Jacob Geerligs
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2020002876A1 publication Critical patent/CL2020002876A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Una vacuna que comprende un componente de antígeno y un componente adyuvante, en donde el componente adyuvante comprende un oligonucleótido inmunoestimulante y una emulsión de agua-en-aceite (W/O), donde el componente antigénico comprende un virus IBD inactivado, y donde el oligonucleótido inmunoestimulante comprende la SEQ ID NO: 8 en una cantidad de 2,5 a 20 µg por dosis.
CL2020002876A 2016-06-02 2020-11-06 Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420) CL2020002876A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344598P 2016-06-02 2016-06-02
US201662365419P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
CL2020002876A1 true CL2020002876A1 (es) 2021-05-07

Family

ID=59215993

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018003420A CL2018003420A1 (es) 2016-06-02 2018-11-30 Vacuna contra la bronquitis infecciosa.
CL2020002876A CL2020002876A1 (es) 2016-06-02 2020-11-06 Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018003420A CL2018003420A1 (es) 2016-06-02 2018-11-30 Vacuna contra la bronquitis infecciosa.

Country Status (15)

Country Link
US (3) US11103573B2 (es)
EP (1) EP3463446A1 (es)
JP (3) JP7659367B2 (es)
KR (6) KR20180129926A (es)
CN (1) CN109152829A (es)
AU (1) AU2017274332B2 (es)
BR (1) BR112018075033A2 (es)
CA (2) CA3175832A1 (es)
CL (2) CL2018003420A1 (es)
CO (1) CO2018012905A2 (es)
MX (3) MX2018014857A (es)
PH (1) PH12018502525A1 (es)
UA (1) UA126562C2 (es)
WO (1) WO2017210244A1 (es)
ZA (3) ZA201807477B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303252A (zh) * 2020-02-17 2020-06-19 青岛易邦生物工程有限公司 一种规模化生产胚毒类抗原的净化方法
TWI911572B (zh) * 2022-10-04 2026-01-11 美商碩騰服務有限責任公司 家禽疫苗及保護家禽之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1357151A1 (en) 2002-04-26 2003-10-29 ATOFINA Research Improved processing of bimodal polymers
ES2322272T3 (es) * 2003-12-23 2009-06-18 Intervet International Bv Vacuna de combinacion para aves de corral.
EP2272949A3 (en) * 2004-03-12 2011-01-19 Wyeth LLC Infectious bursal disease virus antigenic isolates and vaccines
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US8679504B2 (en) * 2008-05-22 2014-03-25 University Of Georgia Research Foundation Inc. Poultry viral materials and methods related thereto
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
AR072976A1 (es) * 2008-08-08 2010-10-06 Wyeth Corp Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
CN101721698B (zh) 2008-10-24 2014-04-02 法罗斯疫苗公司 抗口蹄疫疫苗组合物及其制备和应用
KR101329374B1 (ko) * 2008-12-09 2013-11-14 콜레이 파마시티컬 그룹, 인코포레이티드 면역자극성 올리고뉴클레오타이드
CN102038949A (zh) * 2010-12-29 2011-05-04 青岛易邦生物工程有限公司 鸡新城疫、传染性支气管炎、减蛋综合征、禽流感（h9亚型）四联灭活疫苗的生产方法
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
EP2699318B1 (en) 2011-04-18 2017-08-30 University Of Georgia Research Foundation, Inc. Vaccine delivery method
HUE051277T2 (hu) 2012-11-16 2021-03-01 United Biomedical Inc Szintetikus peptiden alapuló sürgõsségi vakcina ragadós száj- és körömfájás (FMD) ellen
SI3542819T1 (sl) * 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
KR20200039025A (ko) * 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트

Also Published As

Publication number Publication date
KR20240141211A (ko) 2024-09-25
US20250295752A1 (en) 2025-09-25
US11103573B2 (en) 2021-08-31
UA126562C2 (uk) 2022-11-02
BR112018075033A2 (pt) 2019-03-26
AU2017274332A1 (en) 2018-11-22
NZ748375A (en) 2024-07-26
JP7679340B2 (ja) 2025-05-19
JP2019517526A (ja) 2019-06-24
CO2018012905A2 (es) 2018-12-14
KR20220100725A (ko) 2022-07-15
JP2023002541A (ja) 2023-01-10
JP2025041829A (ja) 2025-03-26
US12171825B2 (en) 2024-12-24
US20190240315A1 (en) 2019-08-08
EP3463446A1 (en) 2019-04-10
CA3175832A1 (en) 2017-12-07
NZ788650A (en) 2025-08-29
KR20180129926A (ko) 2018-12-05
KR20210068601A (ko) 2021-06-09
CA3025524C (en) 2023-03-07
KR20220064417A (ko) 2022-05-18
KR102893877B1 (ko) 2025-12-03
NZ788649A (en) 2025-05-30
RU2021117820A (ru) 2021-07-07
ZA202204980B (en) 2022-09-28
ZA202204979B (en) 2022-09-28
RU2018142329A3 (es) 2020-09-01
CA3025524A1 (en) 2017-12-07
MX2018014857A (es) 2019-03-07
CL2018003420A1 (es) 2019-01-18
KR20210068602A (ko) 2021-06-09
WO2017210244A1 (en) 2017-12-07
US20220175911A1 (en) 2022-06-09
RU2018142329A (ru) 2020-06-01
JP7659367B2 (ja) 2025-04-09
ZA201807477B (en) 2023-06-28
PH12018502525A1 (en) 2019-10-21
CN109152829A (zh) 2019-01-04
MX2022007212A (es) 2022-07-12
AU2017274332B2 (en) 2024-06-27
MX2022012910A (es) 2022-11-14

Similar Documents

Publication Publication Date Title
Baz et al. H5N1 vaccines in humans
PH12019501766A1 (en) Porcine coronavirus vaccines
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
AR127585A1 (es) Vacuna de arn de virus sincicial respiratorio
TW201612316A (en) Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition
MX2016012845A (es) Vacuna contra el virus de la diarrea epidemica porcina.
CO2019011548A2 (es) Vacunas contra el gallid herpesvirus 3 recombinante que codifican antígenos patogénicos aviares heterólogos
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
MX388128B (es) Vacuna combinada para cerdos.
MX391930B (es) Vacuna contra la fiebre aftosa.
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
EA201001478A1 (ru) Вакцина
WO2020012428A8 (en) New vaccines against avian reoviruses
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
AR097029A1 (es) Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
PH12020550948A1 (en) Vaccines against hendra and nipah virus infection
UY36208A (es) “bacterias modificadas para vacunas mejoradas contra la brucelosis”.
MX2022012910A (es) Vacuna contra la bronquitis infecciosa.
MX2012002630A (es) Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul.
AR125960A2 (es) Vacuna para uso en aves de corral contra la bursitis infecciosa
AR108664A1 (es) Vacuna contra la bronquitis infecciosa